---
title: "Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds"
description: How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences before new trials begin.
image: https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds

How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences before new trials begin.

![Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds](https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png)\\

Since the first immune checkpoint inhibitor (ICI) was approved by FDA in 2011, the class has grown rapidly. By one analysis, ICIs were second only to kinase inhibitors in oncology approvals between 2000 and 2022 \[1\]. Much of that success comes from their flexibility: by acting on the patient's immune response rather than a specific tumor mutation, the same agent can work across many cancers.

That flexibility creates a hard design question. With CTLA-4, PD-1, and PD-L1 agents available, alone, together, or in sequence, which regimen should a sponsor take into a trial for a given tumor type and patient population? Testing every option clinically is not feasible.

## What QSP modeling does

Quantitative systems pharmacology (QSP) models represent the biology behind a therapy as a system of equations: tumor growth, immune cell trafficking and activation, checkpoint signaling, and the PK and PD of each drug. Building one involves:

- Integrating the cellular and molecular interactions relevant to the mechanism.
- Incorporating known PK and PD data for each agent.
- Calibrating and validating the model against observed clinical outcomes, so it reproduces known results before it is used to predict new ones.
- Generating virtual patient populations whose features reflect the real variability in tumors and immune status.

Once validated, the model can test regimens that have never been run in patients: different combinations, doses, schedules, or sequences, and different patient subgroups.

## Published examples in melanoma and breast cancer

Two published QSP studies illustrate the approach. In melanoma, a model built from clinical data on CTLA-4, PD-1, and PD-L1 blockade was used to predict responses to monotherapy, combination therapy, and sequential therapy \[2\]. In metastatic breast cancer, a systems pharmacology model was used to run an in silico trial of anti-CTLA-4 plus anti-PD-L1 therapy and examine which patient features were associated with response \[3\].

Both studies show the main value of QSP: it turns existing trial data into a way to rank regimens and identify the patients most likely to benefit, before committing to a new study.

## What QSP can and cannot do

Simulations do not replace clinical evaluation. Their role is to make trials more informative: patients are more likely to receive a regimen that suits them, and sponsors gain confidence that a study will answer the question it was designed for. The predictions are only as good as the biology and data in the model, so QSP works best when it is updated as new PK, biomarker, and response data arrive.

## Where biomarker data come in

QSP models for immuno-oncology depend on quantitative biomarker data, such as receptor occupancy, soluble checkpoint ligands, cytokines, and immune cell phenotypes, alongside drug concentrations. Well-validated, consistent measurements across studies are what let a model distinguish one mechanism from another.

Crystal Bio Solutions combines PK, immunogenicity, and biomarker bioanalysis with [clinical pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology) and modeling support to help sponsors make regimen decisions with data. [Contact us](https://www.crystalbiosolutions.com/contact-us) to discuss your combination strategy.

### References

1. Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. *Nat Rev Drug Discov*. 2023;22:625-640. [doi:10.1038/s41573-023-00723-4](https://doi.org/10.1038/s41573-023-00723-4)
2. Milberg O, Gong C, Jafarnejad M, et al. A QSP model for predicting clinical responses to monotherapy, combination and sequential therapy following CTLA-4, PD-1, and PD-L1 checkpoint blockade. *Sci Rep*. 2019;9:11286. [doi:10.1038/s41598-019-47802-4](https://doi.org/10.1038/s41598-019-47802-4)
3. Wang H, Milberg O, Bartelink IH, et al. In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. *R Soc Open Sci*. 2019;6:190366. [doi:10.1098/rsos.190366](https://doi.org/10.1098/rsos.190366)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:54.097Z",
  "datePublished" : "2026-11-22T17:58:54.000Z",
  "headline" : "Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/choosing-checkpoint-inhibitor-combinations-before-the-trial-what-qsp-modeling-adds",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```